Integrated Filing — IndAS



General information about company
Scrip Code 543635
NSE Symbol PPLPHARMA
MSEI Symbol NOTLISTED
ISIN INE0DK501011
Name of company Piramal Pharma Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2025
Date of end of financial year 31-Mar-2026
Date of board meeting when results were approved 28-Jul-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 18-Jul-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter First quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting Single segment
Description of single segment Pharmaceuticals
Start date and time of board meeting 28-Jul-2025   17:30:00
End date and time of board meeting 28-Jul-2025   21:10:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 19337100000
Other income 584000000
Total income 19921100000
2 Expenses
(a) Cost of materials consumed 5243500000
(b) Purchases of stock-in-trade 3428300000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -1731300000
(d) Employee benefit expense 6185900000
(e) Finance costs 861500000
(f) Depreciation, depletion and amortisation expense 1972800000
(f) Other Expenses
1 Other Expenses (Net) 5143700000 5143700000
Total other expenses 5143700000
Total expenses 21104400000
3 Total profit before exceptional items and tax -1183300000
4 Exceptional items 207400000
5 Total profit before tax -975900000
6 Tax expense
7 Current tax 342200000
8 Deferred tax -315400000
9 Total tax expenses 26800000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0
11 Net Profit Loss for the period from continuing operations -1002700000
12 Profit (loss) from discontinued operations before tax 0
13 Tax expense of discontinued operations 0
14 Net profit (loss) from discontinued operation after tax 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 185700000
16 Total profit (loss) for period -817000000
17 Other comprehensive income net of taxes 441400000
18 Total Comprehensive Income for the period -375600000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent -817000000
Total profit or loss, attributable to non-controlling interests 0
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent -375600000
Total comprehensive income for the period attributable to owners of parent non-controlling interests 0
21 Details of equity share capital
Paid-up equity share capital 13248200000
Face value of equity share capital 10
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations -0.62
Diluted earnings (loss) per share from continuing operations -0.62
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0
Diluted earnings (loss) per share from discontinued operations 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations -0.62
Diluted earnings (loss) per share from continuing and discontinued operations -0.62
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results
Textual Information(1) Refer to the consolidated financial results submitted on July 28, 2025, to the Stock Exchange.



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2025
Date of end of reporting period 30-Jun-2025
Whether accounts are audited or unaudited Unaudited
Nature of report standalone or consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurement of Post Employment Benefit Plans -48700000 -48700000
Total Amount of items that will not be reclassified to profit and loss -48700000
2 Income tax relating to items that will not be reclassified to profit or loss -12300000
3 Amount of items that will be reclassified to profit and loss
1 Deferred gains / (losses) on cash flow hedge 12400000 12400000
2 Exchange differences on translation of foreign operations 647400000 647400000
3 Share of other comprehensive income/ (expense) of associates accounted for using the equity method 0 0
Total Amount of items that will be reclassified to profit and loss 659800000
4 Income tax relating to items that will be reclassified to profit or loss 182000000
5 Total Other comprehensive income 441400000